Trials / Completed
CompletedNCT00186667
Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host Disease
An Open Label Study of Sirolimus as Primary Therapy for the Treatment of Chronic GVHD Following Allogeneic Bone Marrow Transplant
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the clinical activity of sirolimus in combination with cyclosporine and corticosteroids as first line therapy for the treatment of chronic Graft Versus Host Disease.
Detailed description
An Open Label Study of Sirolimus as Primary Therapy for the Treatment of Chronic GVHD Following Allogeneic Bone Marrow Transplant
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | high dose chemotherapy and autologous hematopoietic cell transplant |
Timeline
- Start date
- 1999-01-01
- Primary completion
- 2000-01-01
- Completion
- 2005-09-01
- First posted
- 2005-09-16
- Last updated
- 2020-04-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT00186667. Inclusion in this directory is not an endorsement.